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Abstract
Introduction: B cell depletion therapy is efficacious in rheumatoid arthritis (RA) patients failing on tumor necrosis
factor (TNF) blocking agents. However, approximately 40% to 50% of rituximab (RTX) treated RA patients have a
poor response. We investigated whether baseline gene expression levels can discriminate between clinical non-
responders and responders to RTX.
Methods: In 14 consecutive RA patients starting on RTX (test cohort), gene expression profiling on whole
peripheral blood RNA was performed by Illumina® HumanHT beadchip microarrays. Supervised cluster analysis was
used to identify genes expressed differentially at baseline between responders and non-responders based on both
a difference in 28 joints disease activity score (ΔDAS28 < 1.2) and European League against Rheumatism (EULAR)
response criteria after six months RTX. Genes of interest were measured by quantitative real-time PCR and tested
for their predictive value using receiver operating characteristics (ROC) curves in an independent validation cohort
(n = 26).
Results: Genome-wide microarray analysis revealed a marked variation in the peripheral blood cells between RA
patients before the start of RTX treatment. Here, we demonstrated that only a cluster consisting of interferon (IFN)
type I network genes, represented by a set of IFN type I response genes (IRGs), that is, LY6E, HERC5, IFI44L, ISG15,
MxA, MxB, EPSTI1 and RSAD2, was associated with ΔDAS28 and EULAR response outcome (P = 0.0074 and P =
0.0599, respectively). Based on the eight IRGs an IFN-score was calculated that reached an area under the curve
(AUC) of 0.82 to separate non-responders from responders in an independent validation cohort of 26 patients
using Receiver Operator Characteristics (ROC) curves analysis according to ΔDAS28 < 1.2 criteria. Advanced classifier
analysis yielded a three IRG-set that reached an AUC of 87%. Comparable findings applied to EULAR non-response
criteria.
Conclusions: This study demonstrates clinical utility for the use of baseline IRG expression levels as a predictive
biomarker for non-response to RTX in RA.
Introduction
Rheumatoid arthritis (RA) is a systemic autoimmune dis-
ease characterized by chronic inflammation of the joints
that may cause permanent cartilage and bone destruc-
tion. Currently, no curative treatment is available, and
patients are subjected to a prolonged course of treatment.
RA is marked by the presence of rheumatoid factor (RF)
and/or anti-citrullinated protein autoantibodies (ACPA),
which may precede the appearance of clinical symptoms
of arthritis by many years [1,2]. Surface expressing RF B-
cells may bind immune complexes and thereby serve a
role as efficient antigen presenting cells that could lead
to a break in T-cell tolerance against autoantigens [3]. In
addition, an arthritogenic role for ACPA in experimental
models of arthritis has been demonstrated [4,5]. Besides
producers of auto-antibodies, B cells may contribute to
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disease pathogenesis through their role in antigen pre-
sentation, lymphoneogenesis and cytokine release [6].
Therefore, it was suggested that B-cells are essential
players of the disturbed immune system, which fuelled
interest in B-cells as drug target.
Rituximab (RTX) is a chimeric-human monoclonal
antibody directed against the B cell marker CD20 that
effectively depletes CD20-positive B cells. RTX is effica-
cious and safe in RA patients who are failing on TNF
blocking agents [7-9]. Despite the effective depletion of
circulating B cells in nearly all treated patients, clinical
experience revealed that approximately 40% to 50% of
RA patients do not respond to RTX [8,9]. Considering
the progression of damage and the high costs of treat-
ment with biologicals, identification of non-responders
before start of treatment is highly desirable.
Clinical parameters such as baseline disability, number
of previously used TNF blocking agents, and reason for
ineffectiveness of anti-TNF treatment were found to be
associated with non-response to RTX [10,11]. Whereas
fluorescence activated cell sorter (FACS) studies revealed
no association between B cell numbers at baseline and
clinical outcome, highly sensitive FACS technology sug-
gested that the failure for complete B cell depletion at six
months was associated with a poor response [12]. Pooled
data from ten European registries (CARRERA) demon-
strated that seropositive patients achieved significantly
greater reductions in 28 joint disease activity score
(DAS28) at six months than seronegative patients [13].
Others reported associations between BAFF/BLyS levels,
FcgRIII and IL-6 genotype, and Epstein-Barr virus gen-
ome in bone marrow and clinical outcome [10,14,15]. In
addition, preliminary studies suggested an association
between the expression level of transcripts in peripheral
blood cells and clinical outcome [16,17]. Overall these
findings have potential to provide a framework to select
clinically relevant predictors but require validation and
subsequent prognostic evaluation of clinical utility to
warrant further development.
In the present study we focus on further analysis of
transcript biomarkers in predicting response to RTX in
order to determine the value of the proclaimed transcript
markers and extend the transcript profile associated with
response outcome. Key questions that we want to answer
are: 1) Can previously reported transcript markers that
are associated with clinical response be confirmed?; 2)
What is the complexity of the transcript profile that is
associated with responsiveness?; 3) Can we demonstrate
the clinical utility of the transcript markers in an inde-
pendent study? and 4) Can we optimize the transcript
biomarker set to increase its predictive capacity? There-
fore, we started whole genome transcript profiling of
whole peripheral blood cells from patients prior to RTX
treatment to study mRNA levels of all the genes in the
genome simultaneously. Receiver Operating Characteris-
tics (ROC)-curve analysis in an independent validation
study was applied to demonstrate clinical utility and
selection of the most optimal transcript biomarker set.
Materials and methods
Patient recruitment
Forty consecutive RA patients (14 for the test cohort
and 26 for the validation cohort), according to the 1988
revised American College of Rheumatology criteria for
the diagnosis of RA, attending the outpatient clinics of
the VU University medical center and Jan van Breemen
Research Institute|READE scheduled for RTX were fol-
lowed prospectively [18]. Inclusion criteria for this study
are according to the guidelines of the Dutch Society for
Rheumatology for treatment with RTX, that is, active
disease status (defined as DAS28 > 3.2 at treatment
initiation) despite previous treatment with TNF-blocking
agents, unless contraindicated in the opinion of the
treating physician and previous treatment with metho-
trexate (MTX) and one other disease-modifying anti-
rheumatic drug (DMARD). Moreover, patients needed
to have a wash out period of at least one month from
the last TNF blocker and at least six months follow up.
All patients provided written informed consent and both
participating clinics received approval by the local medi-
cal ethics committee. Demographic data and clinical
characteristics are presented in Table 1.
Treatment and clinical evaluation
Patients received RTX 1,000 mg intravenously on days
one and 15 in combination with clemastine (2 mg intra-
venously), methylprednisolone (100 mg intravenously)
and acetaminophen (1,000 mg orally), as premedication.
Four weeks after the first infusion and from 12 weeks on
every three months, the DAS28 was assessed for disease
activity status [19]. After six months the presence of a
clinical nonresponse was defined in two ways: as
ΔDAS28 < 1.2, and as EULAR nonresponse (additionally
requires DAS28 to be > 5.1) [20]. At these visits, serum
and whole blood samples for RNA analysis were collected
using PAXgene tubes (PreAnalytix, GmbH, Hilden, Ger-
many. The use of concomitant DMARDs, prednisolone
or NSAIDs during the study duration was permitted.
Retreatment with RTX or treatment with other biological
agents was prohibited during the six-month follow up.
Laboratory Measurements
RNA isolation
For RNA isolation, 2.5 ml blood was drawn in PAXgene
tubes, incubated for two hours at room temperature and
stored at -20°C. Tubes were thawed overnight at room
temperature prior to RNA isolation. Total RNA was iso-
lated using Bio robot MDX (Qiagen, Benelux b.v.,
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Venlo, The Netherlands) according to the manufac-
turer’s instructions (PAXgene Blood RNA Mdx kit).
Samples were cleaned from salts that may be present
using the Qiagen RNA MinElute procedure according to
the manufacturer’s procedure (Qiagen, Venlo, The
Netherlands). Total RNA concentration was measured
using the Nanodrop spectrophotometer (Nanodrop
Technologies, Wilmington, DE, USA) and RNA purity
and integrity was verified using lab-on-chip technology
(Agilent 2100 Bioanalyzer, Santa Clara, CA, USA).
Microarray analysis
Genome-wide transcriptome data were collected from per-
ipheral blood cells of 14 patients prior to the start of RTX
using baseline transcript data from 13 patients generated
earlier for analysis of the pharmacological changes during
RTX [21], supplemented with baseline data from an addi-
tional patient. Transcriptome data were generated using
the HumanHT-12 v3 Expression BeadChip (Illumina, San
Diego, CA. USA). In this process, 500 ng total RNA was
used to synthesize biotin-labeled cRNA using the Illumina®
TotalPrep™ RNA amplification kit (Ambion, Austin, TX,
USA) and 750 ng biotinylated cRNA was hybridized onto
the Illumina beadchip (ServiceXS, Leiden, the Nether-
lands). Bead summary intensities were log2-transformed
and normalized using quantile normalization [22,23]. All
microarray data have been submitted to the Gene Expres-
sion Omnibus (GEO) under accession number GSE37107.
Hierarchical cluster analysis was used to categorize the
data and TreeView was used to visualize differentially
expressed genes [24]. Baseline characteristics of RA
patients were expressed as mean (SD) or median (inter-
quartile range (IQR)), where appropriate.
cDNA synthesis and quantitative real time PCR
Quantitative real-time PCR was performed on total RNA
samples from the patients in the validation group (n = 26)
using an ABI Prism 7900HT Sequence detection system
(Applied Biosystems, Foster City, CA, USA). RNA (0.5 μg)
was reverse transcribed into cDNA using a RevertAid H-
minus cDNA synthesis kit (MBI Fermentas, St. Leon-Rot,
Germany) according to the manufacturer’s instructions.
Gene expression levels of one housekeeping gene, glyceral-
dehyde-3-phosphate dehydrogenase (GAPDH), and eight
IRGs, that is, LY6E, HERC5, IFI44L, ISG15, MxA, MxB,
EPSTI1 and RSAD2, were determined. To calculate arbi-
trary values of mRNA levels and to correct for differences
in primer efficiencies for each gene a standard curve was
constructed. Expression levels of target genes were
expressed relative to GAPDH.








Age, years 55 ± 10 59 ± 11 58 ± 11
Female, % 86 85 85
Disease characteristics
RA duration, years 11 (5 to 21) 6 (2 to 16) 8 (3 to 17)
DAS28-score 5.7 ± 1.0 5.8 ± 1.2 5.8 ± 1.2
ESR, mm/hr 14 (9 to 31) 29 (13 to 50) 23 (12 to 42)
CRP, mg/L 9 (3 to 19) 14 (6 to 27) 12 (4 to 25)
IgM RF positive, % 71 63 68
ACPA positive, % 79 70 73
Erosive diseases, % 93 59 72
Medication
Previous biologicals, n 2 (1 - 2) 2 (1 - 2) 2 (1 - 2)
> 1 Biological in history, % 50 50 50
Previous DMARDS, n 4 (4 - 5) 3 (3 - 4) 4 (3 - 4)
Current prednisolone use, % 93 63 70
Prednisolone dosage, mg/day 9 (7 - 13) 5 (0 - 10) 8 (0 - 10)
Current DMARD use, % 93 77 83
Current statin use, % 21 13 18
Response
ΔDAS28 -1.6 (-2.7 - -0.5) -1.0 (-1.5 - 0.2) -1.0 (-2.0 - 0.3)








Continuous variables are presented as mean with standard deviation or median with interquartile range where appropriate. ACPA, anti-cyclic citrullinated protein;
CRP, C-reactive protein; DMARD, disease modifying anti-rheumatic drug; ESR, erythrocyte sedimentation rate; HCQ, hydroxychloroquine; MTX, methotrexate; RF,
rheumatoid factor; SSZ, sulphasalazyne;
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Calculation of interferon (IFN) score
An IFN score was calculated as an average of expression
levels of eight IRGs, namely, Ly6E, HERC5, IFI44L,
ISG15, MxA, MxB, EPSTI1 and RSAD2, log2 based.
Where indicated another set of IRGs was used. For uni-
variate analysis and bivariate logistic regression analysis
the IRG response data from both the test and validation
cohort were median centered (as log2 transformed data)
and combined to calculate the IFN score for further
analysis.
Statistical analysis
Statistical analysis on microarray data was performed
using Significance Analysis of Microarray (SAM), version
3.09 [25]. Two class paired analyses using SAM at a false
discovery rate (FDR) of less than 5% between them were
applied to search for single genes that were significantly
differentially expressed between responders and non-
responders upon RTX treatment. Cluster analysis was
used for the categorization of coordinately differentially
expressed genes [24]. TreeView was used to visualize dif-
ferentially expressed genes [26]. Ingenuity pathway analy-
sis [27] was used for pathway level analysis.
Differences in gene expression levels of IFN type I
network genes between patients with a ΔDAS28 > 1.2
versus ΔDAS28 < 1.2 or between EULAR good/moder-
ate versus non-responders were analyzed using the Stu-
dent unpaired t test.
To select the best performing gene set of the eight
IRGs for the ROC-curve performance we calculated the
average expression of all combinations using R [28]. ROC
curves were then constructed by applying the ROC pack-
age [29] available in Bioconductor. Responder status was
based on the ΔDAS28 non-responder status. The Area
under the Curve (AUC) was calculated for each curve
using the AUCi (integrated) function.
Stepwise regression analyses were performed to find
associations between IRG gene expression levels and clini-
cal response. Firstly, crude odds ratios (ORs) with 95%
confidence intervals (CI) were calculated. Due to the num-
ber of patients included, it was not possible to perform
multiple logistic regression analysis. Instead, the associa-
tion between potential predictors and clinical outcome
based on ORs with 95% CIs was compared to that for the
IRG set. Subsequently, potential predictors for RTX
response were added as covariates in a stepwise bivariate
logistic analysis, that is, 1) seropositivity for IgM RF or
ACPA, 2) lower number of previous TNF blocking agents,
3) use of lipid lowering drugs, 4) presence of erosions, 5)
use of prednisolone, and 6) use of methotrexate.
All regression analyses were performed using SPSS
version 15.0 (SPSS, Chicago, IL, USA).
P values < 0.05 are considered to be significant.
Results
Patient characteristics
A total of 40 patients were included, 14 of whom were
subjected to genome-wide gene expression profiling (test
cohort) and 26 of whom were used for validation (valida-
tion cohort). The clinical characteristics of these patients
are shown in Table 1. Concomitant prednisolone use was
lower in the validation cohort, although the daily dosage
was not significantly different. Other characteristics were
not significantly different between the test and validation
cohort.
Interferon Response Genes discriminate between non
responders and responders
In order to identify molecular markers that discriminate
responders from non-responders to RTX in RA we ana-
lyzed the whole blood cell gene expression profile of 14
RA patients before the start of RTX treatment. There-
fore, we searched for genes and/or gene signatures that
were differentially expressed between responders (eight
patients with a ΔDAS28 > 1.2 after six months) and
non-responders (six patients with a ΔDAS28 ≤ 1.2). Sig-
nificant Analysis of Microarrays (SAM) at a FDR of less
than 5% did not reveal differentially expressed genes at
the single gene level. Subsequent analysis based on fold
differences identified a total of 124 genes which differed
at least two-fold in expression level (compared to the
median expression level) in at least three out of the 14
patients. Supervised hierarchical cluster analysis,
wherein patients were categorized as responders and
non-responders based on ΔDAS28, categorized these
124 genes into five groups, which represented different
biological themes. Cluster one consists of genes from
the IFN type I network which are related to IRF (IFN
Regulatory Factor)-activation and IFN type I response
activity. Genes of cluster two belong to processes such
as DNA replication, recombination, and repair. Cluster
three represents genes involved in protein synthesis, and
cell-to-cell signaling and interaction. Genes involved in
hematological system development and function and the
immune cell trafficking network were characteristic for
cluster four. Cluster five consists of genes mainly
involved in immune regulation, such as NFAT regula-
tion, complement system, B-cell development and the
antigen presentation pathway
Next, we analyzed whether clusters of coordinately
regulated genes are associated with clinical outcome
(Figure 1A). The average expression levels of the genes
per cluster were calculated and related to the clinical
ΔDAS28 response status at six months following the
start of RTX treatment. This analysis revealed a signifi-
cant differential expression only of cluster one, consist-
ing of IFN-type I response genes (IRGs). This cluster
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was represented by eight type I IRGs, namely, LY6E,
HERC5, IFI44L, ISG15, MxA, MxB, EPSTI1 and RSAD2,
whose expression levels were highly correlated (r = 0.91)
(Figure 1B, C and 1D). A low expression of IRGs was
associated with a good clinical response, whereas
patients with increased expression of these genes exhib-
ited a poor response (P = 0.0074) (Figure 1C and 2A).
Comparable results were observed when response status
was assessed by the EULAR response criteria in good/
intermediate responders versus non-responders,
although this association did not reach statistical signifi-
cance (P = 0.0599) (Figure 1D and 2B).
Prediction of response to RTX
An important measure of the accuracy of the eight IRG-
set in separating the responders and non-responders is
the ROC curve AUC analysis. Here we used the average
expression values of the eight IRGs as an IFN score to
construct an ROC curve using an independent cohort of
26 patients and calculated the AUC, which was evalu-
ated as a predictor for non-response. At six months
after the start of RTX treatment nine patients were clas-
sified as ΔDAS28 responders and 17 as non-responders.
This analysis revealed an AUC of 0.82 according to the
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Figure 1 Cluster diagrams of genes that were differentially expressed between 14 patients with RA before the start of rituximab
treatment in relation to the ΔDAS28 response outcome at six months. A. Supervised (one-way) hierarchical cluster analysis of baseline
gene expression levels of a set of 124 genes that differed at least two-fold in at least three patients. Genes (rows) that are increased relative to
the mean are indicated in red, decreased in green and genes that show no difference are indicated in black. Patients were stratified based on
changes in ΔDAS28 at six months after the start of treatment in responders (indicated by the orange bar) and non-responders (indicated by
light blue bar) (’change in ΔDAS28’ from low (left) to high (right)). The supervised analysis revealed five gene clusters of which one, consisting of
IRGs, was associated with clinical outcome. B. An expanded view of the subcluster of eight IRGs that is associated with clinical responder status.
C. Cluster of eight IRGs associated with ΔDAS28 clinical responder status. D. Cluster of 8 IRGs associated with EULAR clinical responder status.
DAS28, 28 joints disease activity score; EULAR, European League against Rheumatism; IRG, interferon response genes.
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In order to select the most optimal gene set for response
prediction based on ROC-curve AUC criteria we tested all
combinations of the eight IRGs. For each combination, the
average expression was calculated per patient and ROC
curves were then constructed by applying the ROC pack-
age available in Bioconductor [29]. Responder status was
based on the ΔDAS28 non-responder status. Combina-
tions of three, four or six specific IRGs (EPSTI1, RSAD2,
MxA; or HERC5, RSAD2, MxA, LY6E; or HERC5, IFI44L,
EPSTI1, RSAD2, MxA, LY6E, respectively) revealed the
highest AUC of 0.87 (Figure 3B).
For both the eight IRG and three IRG sets we also calcu-
lated the ROC-curve AUC for the EULAR response out-
come. These analyses revealed an AUC of 0.78 and 0.83,
respectively, demonstrating that these sets also have clini-
cal utility for response prediction based on the EULAR
response criteria (Figure 3C and 3D).
Next, we studied the strength of the association between
the eight IRG-set and non-response in the context of
other potential predictors. We combined the data from
the test and validation cohort. Univariate analysis showed
that the eight gene sets were negatively associated with
clinical response defined as ΔDAS28 < 1.2 (OR: 0.25, 95%
C.I.: 0.09 to 0.70, P = 0.008, Nagelkerke R20.379). Similar
findings were made for the three gene set (OR: 0.25, 95%
C.I.: 0.10 to 0.65, P = 0.004, Nagelkerke R20.42). The IRG
sets outperform the association of other factors such as: 1)
seropositivity for IgM RF or ACPA (OR: 1.6, 95% C.I.: 0.92
to 2.83, P = 0.097); 2) lower number of previous TNF
blocking agents (OR: 0.29, 95% C.I.: 0.077 to 1.06, P =
0.061); 3) use of lipid lowering drugs (OR:1.8, 95% C.I.:
0.35 to 9.41, P = 0.481); 4) presence of erosions (OR:0.63,
95% C.I.: 0.15 to 2.54, P = 0.511); 5) use of prednisolone
(OR:2.0, 95% C.I.: 0.49 to 8.20, P = 0.335); and 6) use of
MTX (OR: 0.3, 95% C.I.: 0.076 to 1.15, P = 0.078). To
determine if the IRG sets are predictors of clinical out-
come independently from the other potential predictors,
stepwise bivariate analysis was performed. These analyses
revealed that adjustment for each single variate, that is, 1)
seropositivity for IgM RF or ACPA; 2) more than one pre-
vious TNF blocking agent; 3) use of lipid lowering drugs;
4) presence of erosions; 5) prednisolone use; and 6) MTX
use as well as age and gender had no significant influence
on the association between IRGs (the eight or three gene
set) and ΔDAS28.
Discussion
B-cell depletion with the anti-CD20 antibody RTX has
proven efficacious in RA [7,8,30]. However, clinical experi-
ence has revealed that approximately 40% to 50% of the
patients show no clinical response. Genome-wide tran-
script profiling technology provides a very powerful and
robust tool allowing an open-ended survey to identify
comprehensively the fraction of genes that are differen-
tially expressed between responders and non-responders
before the start of treatment. This approach identified a
selective group of genes that are all regulated by type I
IFN that is significantly associated with clinical response.
Our results not only confirm but also extend preliminary
results reported previously [17]. In that study a candidate-
gene approach was used to demonstrate an association
between the expression of three randomly picked IRGs
(Mx1, ISG15 and OAS1) by peripheral blood mononuclear
cells (PBMC) and clinical outcome of RTX treatment.
Figure 2 Differential expression of type I interferon (IFN)-response gene activity in relation to clinical responder status to RTX. The
expression levels of eight IRGs (LY6E, HERC5, IFI44L, ISG15, MxA, MxB, EPSTI1 and RSAD2) were determined by quantitative (q)PCR analysis in
peripheral blood cells of patients with RA before RTX treatment. Average expression in Log2 of the eight IRGs was calculated and used as IFN-
score. Data are shown as box plots; each box shows the 25th to 75th percentiles. Student t test analysis revealed a significantly higher IFN-score
in non-responders compared to responders based on ΔDAS28 (P = 0.0074) (A), and EULAR good/intermediate responders (1, 2) versus non-
responders (0) (P = 0.0599) (B). PCR, polymerase chain reaction.
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Here, we further extend this initial observation. Firstly, we
demonstrated that out of all the genes in the human gen-
ome only the IRGs are associated with clinical response to
RTX. We identified a set of eight IRGs whose expression
status could be translated into a score that showed a sig-
nificant correlation with response outcome. Secondly, we
demonstrated clinical utility by showing that the eight
gene-based IFN score predicts the response to RTX using
ROC-curve analysis with an AUC of 0.82 in an indepen-
dent validation cohort. Lastly, advanced data analysis iden-
tified a subset of three gene markers that more accurately
and robustly predicts the response to RTX therapy (AUC
0.87). For the future, larger and prospective multicenter
studies are needed to further validate these findings.
The ROC AUC is an important measure of test accu-
racy. For the eight gene set assay an AUC of 0.82 was
reached, which means that this test correctly classifies
82% of two patients of randomly drawn pairs, which is
considered ‘good’ [31]. Based on these data a cut-off
could be chosen to predict non-response to RTX with a
specificity of 100% and a sensitivity of 44%. Advanced
classifier analysis yielded an AUC of 0.87 for a three
Figure 3 Receiver operating characteristics (ROC) curves for the IRGs as predictor for nonresponse upon RTX treatment in the
validation cohort (n = 26). A. AUC (0.82) for the eight IRG set based on ΔDAS28 response criteria, B. AUC (0.87) for the three IRG set based on
ΔDAS28 response criteria, C. AUC (0.78) for the eight IRG set based on EULAR response criteria (responders and intermediate responders vs. non-
responders) and D. AUC (0.83) for the three IRG set based on EULAR response criteria (responders and intermediate responders versus non-
responders). On the y-axis sensitivity and on the x-axis 1-specificity is indicated. AUC, area under the curve; DAS28, 28 joints disease activity
score; EULAR, European League against Rheumatism; IRGs, interferon response genes; RTX, rituximab.
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gene test, which is considered close to excellent (AUC >
0.90) at separating responders from non-responders.
The association of IRG and RTX outcome appeared
independent of other proclaimed biomarkers for RTX
treatment. Comparable findings were generated based
on the EULAR response outcome measure.
In our study clinical nonresponse at six months was
defined by two composite scoring indices: 1) as ΔDAS28
< 1.2 and 2) as EULAR non-response (additionally
requires DAS28 to be > 5.1). The use of a composite
scoring index could negatively impact the overall
response score since individual components (such as
joint swelling and tenderness) could be the consequence
of irreversible damage in patients who have failed TNF-
blocking therapy, who are the ones that are treated with
RTX. Moreover, a limitation of our study is that we ana-
lyzed the predictive value of IRG for RTX response only
at six months after initiation of RTX. Although this
time point is in line with the time point of the primary
outcome of previous randomized controlled trials in
RTX-treated RA patients [8,9], we would like to evaluate
other time-points as well.
Several investigators have reported on an increased
expression of IRGs in peripheral blood cells in a subset
of RA patients [17,21,32-35]. Evidence for a role of
IFNa and IFNb in the induction of IFN response activ-
ity in RA was provided by Mavragani and colleagues
[33] who demonstrated the concomitant presence of
IFN bioactivity, which could be inhibited by neutralizing
antibodies against IFNa and IFNb, in the serum of RA
patients. Type I IFNs have an essential function in med-
iating innate immune responses against viruses and play
critical roles in several immunological processes includ-
ing lymphoid differentiation, homeostasis, tolerance and
memory. Although an increased expression of IRGs was
associated with the persistence of ACPA after TNF
blockade, a direct relationship between IRG expression
and autoantibody responses in RA could not be con-
firmed [36]. Accordingly, we found that the relationship
between the IRG activity and response outcome was
independent of auto-antibody status.
Results from our study suggest that IFNhigh RA
patients represent a different pathogenic subset of RA
marked by a failure to respond to B-cell depletion ther-
apy. A simple explanation could be that the pathogen-
esis in IFNhigh patients is less dependent on B-cells,
compared to IFNlow patients. However, the IRG activity
was found to be equally present in seropositive and ser-
onegative RA patients, arguing against an association
between IFN-response activity and pathogenic B cells
[36]. Alternatively, a high baseline IFN-activity may be
associated with the presence of a subset of pathogenic B
cells insensitive to the effects of RTX. These could be
present at baseline and could survive in synovial or
bone marrow tissues due to, for example, incomplete B-
cell depletion effectors or concomitant expression of B-
cell survival factors, such as BAFF/BLyS [37]. IFNs may
also affect B-cell differentiation, such as in situ differen-
tiation in CD20- plasma blasts [38].
Pharmacological studies revealed that the regulation of
IRG-activity during treatment is associated with the
IFN-response activity prior to the start of treatment
[21]. The IRG-activity in non-responders, who have an
increased IRG-activity before the start of treatment,
remains stable during treatment, whereas good respon-
ders, who have a low or absent IFN-response activity at
baseline, develop IFN-response activity till a level com-
parable to that of non-responders during three months
of treatment. Thus, baseline IRG-activity appears to be
crucial for the pharmacological induction of type I IFN-
response activity, which might be a critical event in the
ameliorative effect of B-cell depletion therapy in RA.
The increased IFN-activity might explain the increased
BAFF/BLyS levels and persistence of pathogenic B cells
and could explain the change in macrophage function
reflected by an increased BAFF/BLyS, IL10 and CD86
mRNA expression [39].
Conclusions
In conclusion, we applied genome-wide gene expression
technology to identify a set of markers, which accurately
and robustly predict the response to RTX treatment in
an independent validation group of RA patients. There-
fore, these findings are likely to become a substantial
aid to the physician, taking the paradigm of personalized
medicine one step further.
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